Rokit Healthcare achieves preclinical kidney regeneration success with Harvard Medical School

Rokit Healthcare (KOSDAQ: 376900) announced on May 26, 2026 that its AI-driven omentum-based kidney regeneration platform has demonstrated efficacy and safety in preclinical studies conducted with Harvard Medical School researchers. The study, led by Dr. Joseph Bonventre at Harvard-affiliated hospitals, showed that 62.5% of subjects in the omentum patch implant group maintained kidney function as measured by glomerular filtration rate (GFR), while control groups using acellular materials and procedures showed declining function. The technology combines the patient's own omentum tissue with artificial intelligence and 3D bioprinting to create a regenerative patch designed to minimize immune rejection. Rokit Healthcare has filed patents for the technology in South Korea, the United States, and Japan.

This preclinical milestone places Rokit Healthcare at the intersection of two demanding disciplines: bioprinting and regenerative medicine. The company's approach — using the patient's own omentum as a biological scaffold, then applying AI-driven design and 3D bioprinting — addresses the fundamental immune rejection challenge that has historically limited organ-printing efforts. Unlike most bioprinting companies that focus on in-vitro tissue models or simpler skin/cartilage grafts, Rokit Healthcare is targeting solid organ regeneration, specifically chronic kidney disease (CKD), a massive global market with limited therapeutic options beyond dialysis and transplantation. The Harvard collaboration lends credibility that few preclinical-stage bioprinting programs can claim, though the gap between rodent-model GFR data and human clinical outcomes remains wide.

For the AM industry, this is a reminder that bioprinting's value proposition is not about production throughput but about biological functionality. Rokit Healthcare must now execute on its planned domestic pilot clinical trial for CKD patients in the second half of 2026, followed by global trials in South Korea and the United States. The company's ability to scale manufacturing of patient-specific omentum patches under GMP conditions, while navigating FDA and MFDS regulatory pathways, will determine whether this preclinical signal translates into a clinically meaningful product. The technology is promising but remains years away from commercial revenue.